🚨T-minus 4️⃣ weeks to go until the @AmerUrological In-Service and @UroOnc OKAT exams ➡️ prepare to ace your exam with @HighYieldUro 2026 📖 and Q-Bank 💻📱
Presented at #ESMO26:
In patients with muscle-invasive bladder cancer, event-free survival at 24 months was 63.5% with perioperative durvalumab plus neoadjuvant enfortumab vedotin as compared with 45.1% with surgery alone. Full phase 3 VOLGA trial results: nej.md/4z7dQFm@myESMO
ALT A graph showing event-free survival for the durvalumab–enfortumab vedotin (EV) and control groups (intention-to-treat population).
Oral boards prep hasn't appreciably changed in decades, so I built MockUro, an AI examiner that walks you through ~250 canonical urology cases in Socratic Q&A format, grades your free-form answers across key domains, and adapts your study plan to your weak spots
🧵
❓ What's new in the 2026 AUA/SUO NMIBC Guideline?
Last week, we released an amendment to the Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) Guideline.
In this brief video, guideline panel member Dr. Jeff Holzbeierlein highlights key updates, including revised risk classification and new treatment recommendations designed to help clinicians navigate the rapidly evolving non-muscle invasive bladder cancer treatment landscape.
🔗 Check out the guideline now: bit.ly/4xxuZHj